Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH2 Mutation”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Testing effectiveness (Phase 2)Ended earlyNCT03303950
What this trial is testing

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Who this might be right for
AnemiaASXL1 Gene MutationEZH2 Gene Mutation+7 more
University of Utah 6
Not applicableUnknownNCT03499912
What this trial is testing

Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy

Who this might be right for
Acute Myeloid Leukemia
National Taiwan University Hospital 300
Large-scale testing (Phase 3)Active Not RecruitingNCT04164901
What this trial is testing

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Who this might be right for
Grade 2 GliomaResidual GliomaRecurrent Glioma
Institut de Recherches Internationales Servier 331
Early research (Phase 1)UnknownNCT04272957
What this trial is testing

HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms

Who this might be right for
Acute Myeloid Leukemia
Hutchison Medipharma Limited 75
Testing effectiveness (Phase 2)Looking for participantsNCT03683433
What this trial is testing

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Who this might be right for
Acute Bilineal LeukemiaAcute Biphenotypic LeukemiaChronic Myelomonocytic Leukemia+4 more
M.D. Anderson Cancer Center 50
Large-scale testing (Phase 3)Active Not RecruitingNCT03839771
What this trial is testing

Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen Nederland 968
Early research (Phase 1)Active Not RecruitingNCT02632708
What this trial is testing

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Who this might be right for
Newly Diagnosed Acute Myeloid Leukemia (AML)Untreated AMLAML Arising From Myelodysplastic Syndrome (MDS)+2 more
Institut de Recherches Internationales Servier 153
Large-scale testing (Phase 3)Study completedNCT02577406
What this trial is testing

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Who this might be right for
Leukemia, MyeloidIsocitrate Dehydrogenase
Celgene 319
Not applicableUnknownNCT04369287
What this trial is testing

Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaIDH1 Gene MutationIDH2 Gene Mutation
Istituto Clinico Humanitas 654
Early research (Phase 1)Not Yet RecruitingNCT07629089
What this trial is testing

VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations

Who this might be right for
Brain Cancer
Megan Mantica 24
Early research (Phase 1)Active Not RecruitingNCT04603001
What this trial is testing

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)+1 more
Eli Lilly and Company 260
Testing effectiveness (Phase 2)Looking for participantsNCT06577441
What this trial is testing

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Who this might be right for
Myelodysplastic Syndrome
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Looking for participantsNCT06240754
What this trial is testing

Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial

Who this might be right for
Clonal Cytopenia of Undetermined SignificanceCCUS Clonal Cytopenia of Undetermined Significance
Washington University School of Medicine 15
Testing effectiveness (Phase 2)Looking for participantsNCT06176989
What this trial is testing

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Who this might be right for
Metastatic ChondrosarcomaLocally Advanced ChondrosarcomaMetastatic Sinonasal Adenocarcinoma+7 more
National Cancer Institute (NCI) 40
Not applicableStudy completedNCT02986620
What this trial is testing

Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia

Who this might be right for
AML, Adult
Gruppo Italiano Malattie EMatologiche dell'Adulto 388
Testing effectiveness (Phase 2)Study completedNCT03914742
What this trial is testing

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Who this might be right for
IDH1 MutationIDH2 MutationRecurrent Glioblastoma+2 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 67
Testing effectiveness (Phase 2)Active Not RecruitingNCT03825796
What this trial is testing

CPX-351 Plus Enasidenib for Relapsed AML

Who this might be right for
Recurrent Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT06478212
What this trial is testing

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

Who this might be right for
IDH1-mutant GliomaIDH2-mutant Glioma
Institut de Recherches Internationales Servier 51
Testing effectiveness (Phase 2)Study completedNCT04522895
What this trial is testing

IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT

Who this might be right for
Leukemia, Myeloid, AcuteMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+3 more
Heinrich-Heine University, Duesseldorf 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT03744390
What this trial is testing

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromesLeukemia Acute Myeloid
Groupe Francophone des Myelodysplasies 68
Load More Results